Published in Cancer Weekly, November 7th, 2000
The company also reported promising preliminary results from an ongoing Phase I safety trial of Xcytrin for treatment of glioblastoma multiforme (i.e., primary brain tumors). These results were presented at the 42nd Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), held in Boston, Massachusetts, during October 2000.
"Xcytrin appeared to improve local control in the brain, with very few patients...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.